Identifying precisely how a biological or chemical entity interacts with the human cell is fundamental to furthering our understanding of both normal biological and disease processes as well as revealing the mechanism of action of drugs and their potential for toxicity. Retrogenix’s unique cell microarray technology provides a fast, accurate and effective solution for discovering the human cell surface and secreted protein targets of antibodies, proteins, viruses and small molecules. This allows our global pharmaceutical clients to:
Retrogenix’s biologically-relevant system detects specific interactions with a high degree of sensitivity. This unique tool uses proprietary arrays of expression vectors – encoding over 6,200 full-length human plasma membrane and tethered secreted proteins – spotted onto slides. Human cells grown over the top become reverse-transfected resulting in cell surface expression of each respective protein at distinct slide locations. The test molecule is applied and specific binding analysed and confirmed using an appropriate detection system.
Inclusion criteria
Rigorous
*Stringent bioinformatics and literature review for each target (quality prioritised over quantity)
Choice of binding conditions
Fixed or unfixed cells
Biological relevance
Human cell environment
Cell surface expressed proteins; relevant post-translational modifications, folding, dimerisation etc.
Versatile detection method
Immuno-fluorescence (variety of labels, tags & secondaries), 3H for small molecules
Rapid speed
From 3 weeks
Cell therapy specificity screening
Comprehensive
False positive rate
Very low
Reliable screening results
Data for IND/BLA submissions
Validated results
Published studies include: Nature, Cancer Cell, JBC, SLAS, mAbs, JMC, Nature Medicine & JMB.
Widely used
20 / 20 top pharma, plus more than 200 other clients globally
The Retrogenix technology is compatible with a wide range of different ligands. We have successfully screened:
Antibodies and related molecules
mAbs, bispecifics, antibody-drug conjugates (ADCs), antibody fragments such as ScFvs, Fabs DARPins and mimetics, Fc-fusion proteins;
Complex ligands
viruses, organelles and whole cells, including CAR T;
Proteins and peptides
directly fluorescently conjugated or tagged proteins (Fc-tagged, biotinylated, Flag-tagged, His-tagged), monomers, multimers, protein-specific secondaries, polyclonal antisera, purified and media supernatants.
Small molecules
3H-labelled.
Retrogenix has built a high quality library of plasma membrane and secreted proteins for screening ….
Our results have been used in many high impact peer-reviewed publications and multiple patent applications, and are regularly presented at international conferences. Our case studies highlight a selection of these projects providing further details on receptor identification, target deconvolution and specificity screening for biotherapeutics such as CAR T cells and antibodies.
